REDWOOD CITY, Calif., April 14, 2009 (GLOBE NEWSWIRE) -- Threshold Pharmaceuticals, Inc. (Nasdaq:THLD) today announced multiple presentations on its hypoxia-activated prodrug, TH-302. The presentations will take place at the 2009 American Association for Cancer Research (AACR) Annual Meeting being held April 18 - 22, 2009, at the Colorado Convention Center in Denver, CO.
The following presentations will take place:
Poster 230: TH-302 pharmacological activity in 3D multicellular
tumor spheroid models
Meng et al., Sunday, April 19 from 8:00am - 12:00pm
Session Title: Hypoxia in the Microenvironment
Poster 1819: Preclinical dose sequence and regimen optimization of
the hypoxia-activated prodrug TH-302
Sun et al., Sunday, April 19 from 1:00pm - 5:00pm
Session Title: Novel Agents 2
Poster 4517: TH-302, a novel hypoxia-activated prodrug, shows
superior efficacy and less toxicity than ifosfamide
(IFOS) in metastatic and ectopic human lung carcinoma
models
Ahluwalia et al., Tuesday, April 21 from 1:00pm - 5:00pm
Session Title: Agents Causing DNA Damage or Proteosome
Inhibition
Copies of the posters may be obtained by calling the Company.
About Threshold Pharmaceuticals
Threshold is a biotechnology company focused on the discovery and development of drugs targeting Tumor Hypoxia, the low oxygen condition found in microenvironments of most solid tumors. This approach offers broad potential to treat most solid tumors. By selectively targeting tumor cells, we are building a pipeline of drugs that hold promise to be more effective and less toxic to healthy tissues than conventional anticancer drugs. For additional information, please visit our website (www.thresholdpharm.com).
Forward-Looking Statements
Except for statements of historical fact, the statements in this press release are forward-looking statements, including statements regarding Threshold's product candidates, and potential therapeutic uses and benefits of our product candidates. These statements involve risks and uncertainties that can cause actual results to differ materially from those in such forward-looking statements. Potential risks and uncertainties include, but are not limited to, Threshold's ability to commence its anticipated clinical trials, the time and expense required to conduct such clinical trials and analyze data, issues arising in the regulatory or manufacturing process and the results of such clinical trials (including product safety issues and efficacy results). Further information regarding these and other risks is included under the heading "Risk Factors" in Threshold's Annual Report on Form 10-K, which was filed with the Securities Exchange Commission on March 13, 2009 and is available from the SEC's website (www.sec.gov) and on our website (www.thresholdpharm.com) under the heading "Investors." We do not intend to update any forward-looking statement made in this news release.